Pharmaceutical company Orion Biotechnology Canada Ltd reported on Monday that it received feedback from the Food and Drug Administration (FDA) to facilitate the preparation and submission of the Pre-Investigational New Drug (PIND) application of its lead candidate OB-002O in 2020.
The company added that the PIND was focused on the development of OB-002O as an agent for the treatment of solid tumours. The OB-002 is a chemokine analogue CCR5 antagonist that is being developed in a topical form for HIV prevention (OB-002H) as well as an intravenous immunotherapy agent (OB-002O).
According to the company, CCR5 antagonism has been shown to induce anti-cancer effects in preclinical and Phase 1 clinical studies of colorectal cancer (Halama et al. Cancer Cell 2016) and is an active area of cancer drug development.
In conjunction, the use of OB-002 alone, or in combination with a checkpoint inhibitor, was efficacious in the CT-26 syngeneic colorectal cancer model, which provided the rationale for this Pre-IND submission, concluded the company .
Langhua Pharmaceutical passes US FDA's on-site inspection
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting